16 results
IDSA Recommendations for Preventing and Treating HHV-8 Diseases—Kaposi Sarcoma (KS), Primary Effusion Lymphoma (PEL), Multicentric Castleman’s
recommended for KS treatment ... IDSA #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
duration same as for treatment ... Note: Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
itraconazolea 200 mg PO BID ... IDSA #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
suspension 400 mg PO BID ... for effective treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Isospora belli Infection in HIV-AIDS
Treating Isospora belli Infection
General Management Considerations:
 • Fluid
Infection General Management ... IDSA #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Herpes Simplex Virus (HSV) Infections in HIV-AIDS
Treating Orolabial Lesions (Duration: 5–10 days)
• Continue treatment ... IDSA #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Managing Cryptosporidiosis in HIV-AIDS
Preventing Chronic Cryptosporidiosis:
 • Because chronic cryptosporidiosis occurs
should prevent the disease ... 500–1000 mg PO BID ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Treponema pallidum Infections (Syphilis) to Prevent Disease in HIV-AIDS
Early Stage (Primary, Secondary,
consultation to guide management ... IDSA #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Cytomegalovirus Infections in HIV-AIDS
Preventing CMV Disease:
 • CMV end-organ disease is best
Preventing CMV Disease ... Valganciclovir 900 mg PO BID ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Coccidiodomycosis in HIV-AIDS
Treating Mild Infections (Such As Focal Pneumonia or asymptomatic patients
Extrathoracic Disseminated Disease ... IDSA #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology